Anika Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
12/03/2025 21:02
Anika Therapeutics Inc ANIK.OQ reported a quarterly adjusted loss of $1.50 per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-4.30. The mean expectation of two analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -51 cents to -8 cents per share. Revenue fell 28.8% to $30.60 million from a year ago; analysts expected $29.00 million. Anika Therapeutics Inc's reported EPS for the quarter was a loss of $1.50. The company reported a quarterly loss of $21.87 million. Anika Therapeutics Inc shares had risen by 2.0% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 1,866.7% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "strong buy" Wall Street's median 12-month price target for Anika Therapeutics Inc is $26.50 This summary was machine generated from LSEG data March 12 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.29 | -1.50 | Missed |
| Sep. 30 2024 | -0.01 | -0.25 | Missed |
| Jun. 30 2024 | 0.05 | -0.01 | Missed |
| Mar. 31 2024 | -0.19 | -0.31 | Missed |